Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
about
Targeting hypoxic response for cancer therapyQuality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer.Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.Novel anti-angiogenic therapeutic strategies in colorectal cancer.Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.VEGFR2 regulates endothelial differentiation of colon cancer cells.A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer.Durable complete remission following anti-EGFR antibodies in recurrent metastatic colorectal cancer.CONCORD biomarker prediction for novel drug introduction to different cancer types.Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review.The role of tumor microenvironment in resistance to anti-angiogenic therapy.Who will benefit more from maintenance therapy of metastatic colorectal cancer?Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis.
P2860
Q26767351-18CBFDA2-C154-4443-9304-F81DAFFE2BF9Q30313818-B24BE2F3-F9E1-43C6-96C1-DDD98444EB3CQ36143977-F91CCC70-64ED-4397-90D1-F332B931C127Q37362955-78F686D1-3F1D-42F4-AC08-C978421B5054Q38666172-E2EF9A69-AA80-4D48-A517-1E9023CA5889Q38757723-DF877F69-9A12-4291-8B87-43BE69ABF43FQ38759141-5BC430AB-5814-4015-A467-ACFF73FB140CQ38941928-FE10A295-B345-4197-9184-FE5C8FE0AE46Q38948950-93A62F5E-55EC-42D3-A5C0-7004144F1660Q39110385-F1798AB5-7836-45D2-BB18-D7A06878148AQ41570454-1544B266-EFC3-4BEF-B1F7-BA32818AAF4DQ47578424-4912E449-EE4B-41D6-89D0-51240BB86140Q48285173-AEE628D7-E659-4099-9668-7CFB28D65744Q50128212-DBF79027-708A-4D20-89A5-9FAFDA7E5E6BQ50350183-028637A7-12A5-4A55-ADE8-6C8007AA1334Q52645823-EB94F64B-1FCD-4DB3-AA91-02EBD7C91863Q52649576-31458EAA-A1DC-4351-AAAD-AE663DA22DCCQ55446762-A62350AC-1E29-4EE9-8B3F-9D785DB33E2D
P2860
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Bevacizumab with or without er ...... ed, open-label, phase 3 trial.
@en
Bevacizumab with or without er ...... ed, open-label, phase 3 trial.
@nl
type
label
Bevacizumab with or without er ...... ed, open-label, phase 3 trial.
@en
Bevacizumab with or without er ...... ed, open-label, phase 3 trial.
@nl
prefLabel
Bevacizumab with or without er ...... ed, open-label, phase 3 trial.
@en
Bevacizumab with or without er ...... ed, open-label, phase 3 trial.
@nl
P2093
P921
P1433
P1476
Bevacizumab with or without er ...... ed, open-label, phase 3 trial.
@en
P2093
Aimery de Gramont
Annette K Larsen
Benoist Chibaudel
Benoit Samson
Christophe Louvet
Christophe Tournigand
Dewi Vernerey
Franck Bonnetain
Frédéric Viret
Gérard Lledo
P304
P356
10.1016/S1470-2045(15)00216-8
P577
2015-10-22T00:00:00Z